← Back

Wire · opportunities

FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group ...

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at neurologylive.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA approved two new treatments for adults with acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG), gefurulimab and cemdisiran, expanding patient treatment options. Additionally, the phase 3 POLARIS-AD trial showed AR1001 slowed clinical decline in the monotherapy population with early Alzheimer's disease.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have new treatment options for generalized myasthenia gravis that offer distinct dosing schedules and mechanisms. Alzheimer's drug developers must note AR1001's promise in early monotherapy, signalling a niche to target amid broader trial challenges.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgmgalzheimersclinical-trialneurologyrare-diseases